广州医药
廣州醫藥
엄주의약
GUANGZHOU MEDICAL JOURNAL
2014年
5期
18-20
,共3页
陈少红%伍丽琼%王小拍%杜洪
陳少紅%伍麗瓊%王小拍%杜洪
진소홍%오려경%왕소박%두홍
结外鼻型 NK/T 细胞淋巴瘤%CD30%临床病理特征
結外鼻型 NK/T 細胞淋巴瘤%CD30%臨床病理特徵
결외비형 NK/T 세포림파류%CD30%림상병리특정
Extranodal NK/T cell lymphoma,Nasal type%CD30%Clinical pathological feature
目的探讨 CD30在结外鼻型 NK/T 细胞淋巴瘤(NKTCL)中的表达及其意义。方法免疫组织化学检测 CD30在30例 NKTCL 中的表达,同时分析 CD30的表达与 NKTCL 临床病例特征之间的关系。结果NKTCL CD30的表达率为30.0%(9/30);患者5年总体生存率与 CD30的表达有显著关系(P =0.032);CD30表达与患者的肿瘤分级有关(P =0.035);Cox 回归分析显示,CD30在统计学上可以作为独立预后指标(P =0.003)。结论CD30的表达与 NKTCL 患者5年总体生存率有关,而且也许可以作为一个独立的预后指标。
目的探討 CD30在結外鼻型 NK/T 細胞淋巴瘤(NKTCL)中的錶達及其意義。方法免疫組織化學檢測 CD30在30例 NKTCL 中的錶達,同時分析 CD30的錶達與 NKTCL 臨床病例特徵之間的關繫。結果NKTCL CD30的錶達率為30.0%(9/30);患者5年總體生存率與 CD30的錶達有顯著關繫(P =0.032);CD30錶達與患者的腫瘤分級有關(P =0.035);Cox 迴歸分析顯示,CD30在統計學上可以作為獨立預後指標(P =0.003)。結論CD30的錶達與 NKTCL 患者5年總體生存率有關,而且也許可以作為一箇獨立的預後指標。
목적탐토 CD30재결외비형 NK/T 세포림파류(NKTCL)중적표체급기의의。방법면역조직화학검측 CD30재30례 NKTCL 중적표체,동시분석 CD30적표체여 NKTCL 림상병례특정지간적관계。결과NKTCL CD30적표체솔위30.0%(9/30);환자5년총체생존솔여 CD30적표체유현저관계(P =0.032);CD30표체여환자적종류분급유관(P =0.035);Cox 회귀분석현시,CD30재통계학상가이작위독립예후지표(P =0.003)。결론CD30적표체여 NKTCL 환자5년총체생존솔유관,이차야허가이작위일개독립적예후지표。
Objective To investigate the pathological and clinical significance of CD30 in extranodal nasal type NK/T cell lymphoma (NKTCL). Methods We detected CD30 expression using immunohistochemistry staining in 30 cases of NK-TCL.Moreover,we analyzed the relationship between CD30 and the clinical pathological features of NKTCL. Results Our re-sults showed that CD30 expression was found in 30.0%(9 /30);CD30 expression was associated with 5-year overall survival rate (P =0.032)as well as tumor stage (P =0.035).Moreover,Cox regression test showed that CD30 expression were statistically independent prognostic factors for NKTCL patients(P =0.003). Conclusion Our results suggested that 5-year overall survival rate of NKTCL patients was associated with CD30 expression which may be considered as an independent prognostic factor.